Lansoprazole is a member of benzimidazoles, a member of pyridines and a sulfoxide. It has a role as an EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor and an anti-ulcer drug. ChEBI Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux disease (GERD) along with other pathologies caused by excessive acid secretion. DrugBank Lansoprazole is a Proton Pump Inhibitor. The mechanism of action of lansoprazole is as a Proton Pump Inhibitor. The physiologic effect of lansoprazole is by means of Inhibition Gastric Acid Secretion. FDA Pharm Classes View More…